Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05147350 · ClinicalTrials.gov registry record · Phase 1
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
A Phase 1 study, sponsored by Debiopharm International.
- Terminated
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT05147350 is a Phase 1 study that was terminated before completion, run by Debiopharm International. The registered enrollment target is 38 participants.
The verdict
NCT05147350, a Phase 1 study, was terminated before completion, sponsored by Debiopharm International.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess preliminary anti-tumor activity.
Interventions
- DRUG RP-6306 (oral PKMYT1 inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-08-09 |
| Est. Completion | 2025-02-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05147350
The ClinicalTrials.gov registry entry for NCT05147350 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RP-6306 (oral PKMYT1 inhibitor) is the first listed.
NCT05147350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05147350 about?
NCT05147350 is a clinical study titled "Study of RP-6306 With FOLFIRI in Advanced Solid Tumors". The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess preliminary anti-tumor activit...
What is the current status of trial NCT05147350?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2022-08-09. Estimated completion is 2025-02-12.
What interventions are being tested in trial NCT05147350?
The interventions under investigation include: RP-6306 (oral PKMYT1 inhibitor) (DRUG).
Who is sponsoring clinical trial NCT05147350?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.